Denice Torres
CIK: 0001820278
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 25, 2026CLDX
Celldex Therapeutics, Inc.
Award(A)DirectNon-Qualified Stock Option (right to buy)
26K shares- - May 28, 2026GKOS
GLAUKOS Corp
Award(A)DirectStock Option (Right to Buy)
3K shares- - May 28, 2026GKOS
GLAUKOS Corp
Award(A)Direct1.9K shares- - May 4, 2026SPTX
Seaport Therapeutics, Inc.
Conversion(C)Indirect13.4K shares- - Apr 30, 2026SPTX
Seaport Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
12.3K shares- - Jan 2, 2026GKOS
GLAUKOS Corp
Award(A)Direct623 shares- - Jun 5, 2025CLDX
Celldex Therapeutics, Inc.
Award(A)DirectNon-Qualified Stock Option (right to buy)
33K shares- - May 29, 2025GKOS
GLAUKOS Corp
Award(A)Direct2.1K shares- - May 13, 2025TSVT
2seventy bio, Inc.
Tender Offer(U)Direct19.5K shares- - May 13, 2025TSVT
2seventy bio, Inc.
Disposition(D)Direct12.1K shares- - Jan 2, 2025GKOS
GLAUKOS Corp
Award(A)Direct461 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 |  CLDX Celldex Therapeutics, Inc. | Award(A) Non-Qualified Stock Option (right to buy) | 26,000 | - | - | Direct |
| May 28, 2026 |  GKOS GLAUKOS Corp | Award(A) Stock Option (Right to Buy) | 2,987 | - | - | Direct |
| May 28, 2026 | GKOS GLAUKOS Corp | Award(A) | 1,878 | - | $0 | Direct |
| May 4, 2026 |  SPTX Seaport Therapeutics, Inc. | Conversion(C) | 13,406 | - | $0 | Indirect |
| Apr 30, 2026 | SPTX Seaport Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 12,258 | - | - | Direct |
| Jan 2, 2026 | GKOS GLAUKOS Corp | Award(A) | 623 | - | $0 | Direct |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | Award(A) Non-Qualified Stock Option (right to buy) | 33,000 | - | - | Direct |
| May 29, 2025 | GKOS GLAUKOS Corp | Award(A) | 2,108 | - | - | Direct |
| May 13, 2025 |  TSVT 2seventy bio, Inc. | Tender Offer(U) | 19,510 | - | - | Direct |
| May 13, 2025 | TSVT 2seventy bio, Inc. | Disposition(D) | 12,050 | - | - | Direct |
| Jan 2, 2025 | GKOS GLAUKOS Corp | Award(A) | 461 | - | - | Direct |
1-11 of 11 transactions
About Torres Denice
Torres Denice (SEC CIK 0001820278) files insider reports with the SEC as Director of Celldex Therapeutics, Inc. (CLDX), Director of GLAUKOS Corp (GKOS) and Director of Seaport Therapeutics, Inc. (SPTX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 9 ownership filings by Torres Denice (1 Form 3, 8 Form 4), filed between May 15, 2025 and Jun 29, 2026. Those filings report 11 transactions, from Jan 2, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Torres Denice's filings is in ALISO VIEJO, CA.
Recent filings by Torres Denice
- Jun 25, 2026: Grant or award of CLDX derivative securities (Form 4, code A).
- May 28, 2026: Grants or awards of GKOS derivative securities (2 lines, Form 4, code A).
- May 4, 2026: Conversion of SPTX shares (Form 4, code C).
- Apr 30, 2026: Grant or award of SPTX derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of GKOS shares (Form 4, code A).
Other insiders filing for Celldex Therapeutics, Inc. (CLDX)
- Lawver Teri L, SVP & Chief Commercial Officer
- Jimenez Freddy A., SVP & GENERAL COUNSEL
- Young Diane C., SVP, CHIEF MEDICAL OFFICER
- Heath-Chiozzi Margo, SVP OF REGULATORY AFFAIRS
- Martin Samuel Bates, SVP AND CFO
- Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN.